Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Syn-Ake? Benefits, Research & Safety
A tripeptide that mimics the neuromuscular blocking effects of Temple Viper venom (waglerin-1), targeting nicotinic acetylcholine receptors to reduce expression lines.
Also known as:
Dipeptide Diaminobutyroyl Benzylamide Diacetate
Snake Venom Peptide
Waglerin-1 Mimetic
SYN-AKE
UK summary: Cosmetic peptide (snake-venom-mimetic) regulated under UK cosmetics legislation. Topical only. Marketing leans on the venom-mimetic story; effect size is modest.
Quick Facts
Category
Longevity & Anti-Ageing
Half-Life
Effects persist while product remains on skin; consistent daily application required for maintained benefits
UK Status
Approved cosmetic ingredient. Listed in the INCI dictionary as Dipeptide Diaminobutyroyl Benzylamide Diacetate. Available in over-the-counter skincare products.
EU Status
Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
Overview
Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic tripeptide designed to mimic the neuromuscular blocking properties of waglerin-1, a peptide found in the venom of the Temple Viper (Tropidolaemus wagleri). Developed by Pentapharm (now part of DSM), Syn-Ake represents a novel approach to expression line reduction by targeting acetylcholine receptors directly rather than the vesicle release machinery.
While Argireline and SNAP-8 work by interfering with the SNARE complex (blocking neurotransmitter release), Syn-Ake works at the receptor level—competing with acetylcholine for binding to nicotinic acetylcholine receptors on muscle cells. This fundamentally different mechanism provides a potentially complementary approach to neuromuscular peptides.
The Temple Viper's venom has been studied for its ability to cause muscular relaxation in prey. Waglerin-1, the active component, binds to muscle-type nicotinic receptors with high affinity. Syn-Ake is a small, stable tripeptide that mimics this binding without the toxicity of the full venom peptide.
Clinical studies have demonstrated Syn-Ake's ability to reduce forehead wrinkle depth, with effects observable within 28 days of regular application. Its unique mechanism makes it particularly interesting for combination with SNARE-targeting peptides for multi-pathway expression line reduction.
**Important Note:** Syn-Ake is a cosmetic ingredient for topical use only. Effects are more subtle than injectable neurotoxins, and the peptide is entirely safe—sharing no toxicity with actual snake venom.
Evidence standards summary
Syn-Ake — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.
Cosmetic peptide (snake-venom-mimetic) regulated under UK cosmetics legislation. Topical only. Marketing leans on the venom-mimetic story; effect size is modest.
02Human evidence grade
DAnimal/cell evidence onlyStrength of evidence from published human trials.
03Preclinical evidence grade
CLimited human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Approved cosmetic ingredient. Listed in the INCI dictionary as Dipeptide Diaminobutyroyl Benzylamide Diacetate. Available in over-the-counter skincare products.
- EU: Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
- Notes: Syn-Ake is a fully approved cosmetic ingredient with an excellent safety record. Despite its 'snake venom' marketing, it is a synthetic tripeptide with no relationship to actual venom toxicity. It is legal for sale in consumer products and has been used safely for nearly two decades. Not prohibited in sports as it is a topical cosmetic ingredient.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Snake-venom-like wrinkle eraser.
- Replaces Botox topically.
07Common internet claims
- Marketed in premium cosmetic skincare on the 'snake venom' story.
- Sold in serums and creams.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Botox-like effect from snake venom mimetic” | D | Limited | Moderate | Mechanism is loosely analogous to alpha-bungarotoxin; topical clinical effect on wrinkles is modest and well short of injectable botulinum toxin. |
09Safety uncertainty score
Low — well characterised
Safety profile is well-characterised in published human data.
10Known adverse signals
- Topical use well tolerated.
- Rare skin sensitivity.
11Drug-interaction uncertainty
Low
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
WADA: Low sport riskWADA strict-liability framing applies.
13UK legal position
UK: Licensed medicine (UK)
Approved cosmetic ingredient. Listed in the INCI dictionary as Dipeptide Diaminobutyroyl Benzylamide Diacetate. Available in over-the-counter skincare products.
14EU legal position
Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
15What this page cannot tell you
- Whether independent finished-product RCTs support the manufacturer claims.
- Effect size in comparison to in-clinic botulinum toxin (it is much smaller).
16Last reviewed
17Citation quality score
DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Independent comparative trials sparse.
19Safer alternatives / established care pathways
- Sunscreen + topical retinoid.
- In-clinic botulinum toxin for expression-line reduction.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate cosmetic addition for me?
Discovery & History
Syn-Ake was developed by Pentapharm, a Swiss biotechnology company specialising in active ingredients for cosmetics and pharmaceuticals. The development was inspired by research into the Temple Viper (Tropidolaemus wagleri) and its unique venom composition.
The Temple Viper, native to Southeast Asia, produces a venom containing waglerin peptides that cause reversible muscular paralysis. Unlike most snake venoms that work through enzymatic destruction of tissues, waglerin causes a non-destructive, reversible blockade of nicotinic acetylcholine receptors—making it scientifically interesting for cosmetic applications.
Pentapharm's researchers sought to create a synthetic peptide that could replicate waglerin's receptor-blocking activity without the full complexity or potential risks of the natural venom peptide. The result was Syn-Ake—a small tripeptide that competitively binds to nicotinic receptors.
The peptide was introduced to the cosmetic market in the mid-2000s and quickly gained attention for its novel mechanism. Unlike Argireline and other SNARE-targeting peptides, Syn-Ake offered a completely different approach to neuromuscular modulation.
Pentapharm was acquired by DSM (Dutch State Mines), a global science-based company, which continues to manufacture and market Syn-Ake as part of their cosmetic ingredients portfolio. The peptide has been incorporated into numerous premium anti-ageing products worldwide.
The "snake venom" marketing angle has made Syn-Ake popular in consumer products, though scientists emphasise that the synthetic peptide shares only the mechanism—not the risks—of actual venom components.
Mechanism of Action
Syn-Ake exerts its anti-wrinkle effects through a mechanism distinct from other neuromuscular peptides:
**Nicotinic Acetylcholine Receptor Antagonism**
Unlike Argireline/SNAP-8 (which block neurotransmitter release) or Leuphasyl (which reduces release signals), Syn-Ake works at the post-synaptic receptor level by competing with acetylcholine for binding to nicotinic receptors.
**Neuromuscular Junction Physiology**
Normal muscle contraction involves:
1. Nerve impulse arrives at neuromuscular junction
2. Acetylcholine is released from nerve terminal
3. Acetylcholine binds to nicotinic receptors on muscle cell
4. Receptor activation causes muscle contraction
5. Acetylcholinesterase breaks down acetylcholine, ending the signal
**Syn-Ake's Intervention Point**
Syn-Ake intervenes at step 3—the receptor binding stage:
- Competes with acetylcholine for receptor binding sites
- When Syn-Ake occupies receptors, acetylcholine cannot bind
- Reduced receptor activation leads to attenuated muscle contraction
- Expression lines gradually soften as mechanical stress decreases
**Waglerin Mimicry**
Waglerin-1 from Temple Viper venom is a 22-amino acid peptide that binds with high affinity to muscle-type nicotinic receptors. Syn-Ake replicates the critical receptor-binding motif in a minimised 3-amino acid structure, providing:
- Stable, reproducible synthesis
- No toxicity (the small peptide lacks venom's harmful properties)
- Suitable molecular size for topical penetration
- Reversible, competitive antagonism
**Complementary to SNARE-Targeting Peptides**
Syn-Ake's receptor-level mechanism is complementary to Argireline/SNAP-8's vesicle-level mechanism:
- **SNARE peptides:** Reduce acetylcholine RELEASE
- **Syn-Ake:** Blocks acetylcholine RECEPTION
- **Combined:** Dual-pathway neuromuscular modulation
This creates potential for synergistic effects when combining Syn-Ake with Argireline or SNAP-8—addressing both the release and reception phases of neuromuscular signalling.
**Muscle Relaxation Without Paralysis**
Like all cosmetic neuromuscular peptides, Syn-Ake:
- Reduces contraction intensity rather than blocking completely
- Effects are dose-dependent and reversible
- Cannot cause frozen expressions or drooping
- Works best on dynamic wrinkles caused by repeated expressions
Researched Benefits
Based on preclinical and clinical research findings:
- 1Clinical studies demonstrated 52% reduction in forehead wrinkle depth after 28 days
- 2Unique receptor-level mechanism distinct from SNARE-targeting peptides
- 3Potential synergy with Argireline/SNAP-8 for multi-pathway expression line reduction
- 4Visible softening of forehead lines and crow's feet
- 5Rapid onset of effects—improvements seen within 2-4 weeks
- 6Well-tolerated with excellent safety profile
- 7No connection to actual snake venom toxicity—completely safe tripeptide
- 8Stable in cosmetic formulations across various product types
- 9Suitable for combination with collagen-stimulating peptides
- 10Reversible effects without risk of muscle weakness or paralysis
Claim vs Evidence
How popular claims about Syn-Ake stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Botox-like effect from snake venom mimetic” | D | Limited | Moderate | Mechanism is loosely analogous to alpha-bungarotoxin; topical clinical effect on wrinkles is modest and well short of injectable botulinum toxin. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Typically used at 1-4% concentration in topical formulations; often combined with other neuromuscular peptides |
| Frequency | Applied twice daily to expression line areas (forehead, crow's feet, frown lines) |
| Duration | Clinical studies showed significant results at 28 days; optimal effects with continued use over 8+ weeks |
| Notes | Syn-Ake is a cosmetic ingredient available in premium anti-ageing products. Apply to clean, dry skin on areas with expression lines. Works best on dynamic wrinkles. Consider combining with SNARE-targeting peptides (Argireline/SNAP-8) for dual-pathway effects, and collagen peptides (Matrixyl) for comprehensive anti-ageing. |
Administration Routes
Routes studied in research settings (educational only):
- Topical application in serums (most common)
- Topical application in creams and lotions
- Topical application in targeted eye treatments
- Topical application in forehead-specific formulations
- Topical application in multi-peptide anti-ageing products
| Half-Life | Stability |
|---|---|
| Effects persist while product remains on skin; consistent daily application required for maintained benefits | Stable in properly formulated products at appropriate pH; should be stored in cool, dark conditions; typically 12-24 month shelf life in sealed products |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Very well tolerated—side effects are rare
- Mild skin irritation possible in sensitive individuals (uncommon)
- Temporary redness at application site (rare)
- Slight tingling on initial application (occasional)
Rare Risks & Concerns
- Allergic reactions (very rare with peptides)
- Eye irritation if product enters eyes
- No connection to snake venom toxicity—completely synthetic and safe
Contraindications
- Known allergy to peptides or specific formulation components
- Active skin infections at application site
- Open wounds or broken skin
- Those with myasthenia gravis or neuromuscular disorders should consult physician (theoretical concern)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Approved cosmetic ingredient. Listed in the INCI dictionary as Dipeptide Diaminobutyroyl Benzylamide Diacetate. Available in over-the-counter skincare products.
🇪🇺 European Union
Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
Syn-Ake is a fully approved cosmetic ingredient with an excellent safety record. Despite its 'snake venom' marketing, it is a synthetic tripeptide with no relationship to actual venom toxicity. It is legal for sale in consumer products and has been used safely for nearly two decades. Not prohibited in sports as it is a topical cosmetic ingredient.
Clinical Studies Summary
Looking for Syn-Ake?
Source research-grade Syn-Ake from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Syn-Ake
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate cosmetic addition for me?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreMatrixyl
A pioneering signal peptide that mimics natural collagen-boosting messengers, extensively validated in clinical studies for wrinkle reduction and skin firmness improvement.
Learn moreArgireline
A neuromodulating hexapeptide that reduces facial muscle contractions through SNARE complex inhibition, providing a topical alternative to botulinum toxin for expression line reduction.
Learn moreSNAP-8
An enhanced 8-amino acid version of Argireline with improved penetration and efficacy for reducing expression lines through SNARE complex modulation.
Learn moreLeuphasyl
A 5-amino acid neuromuscular peptide that reduces expression lines through the enkephalin pathway, enhancing the effects of Argireline and SNAP-8.
Learn more